Clinical Trial Search

Primary: Daily Prolonged Sedentary Bouts (activPAL+FitSitt Sensors) Change From Baseline to up to 7 Days With Intervention Present — -1.7100 hours/24-hr period — p=0.007

Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters

Primary: Change in Composite Measure of Care Quality — 7.0; 4.5; 5.9; 5.9 Change in percent — p=0.19

Primary: Percentage of HHCs With Virological Influenza Transmission by Day 5 — 13.42; 9.50 percentage of HHCs — p== 0.013

Primary: Number of Participants Completing Visits — 7; 11 Participants

Primary: Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase. — 3; 1; 1; 1 Participants — p=0.0215

Primary: Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. — 3.00; 5.2; 4.7; 5.0 log10 RNA copies/mL/days

Primary: Number of Participants With No Alcohol Use — 0; 0; 0 Participants

Primary: Acceptability Quantitative — 3.5 score on a scale

Primary: Overall Response Rate (ORR) — 48.5 Percentage of patients with response

Primary: Pain Intensity — 4.2; 4.1; 4.0 score on a scale

Primary: Percentage of Participants Achieving a Successful Composite Clinical Response According to the Criteria for American College of Rheumatology 20% Response (ACR20) — 48.4…

Primary: Hormone Analysis — 70.7; 57.8; 114; 97.3 ng/mL

Primary: The Proportion of Participants With Shigellosis Following Challenge With Shigella Sonnei 53G Through Day 63 in the Pooled Group of Participants Receiving Two Doses of…

Primary: Client Satisfaction Questionnaire — 29.7; 27.9 score on a scale